Anticoagulant strategies for the patient with chronic kidney disease

Jonathan P. Law, Luke Pickup, Jonathan N. Townend, Charles J. Ferro

Research output: Contribution to journalArticlepeer-review


Chronic kidney disease (CKD) is a global health problem affecting up to 14% of the adult population in developed countries. On the basis of current guidelines, patients with CKD will often fulfil criteria for both short-term and long-term anticoagulation. Paradoxically, patients with CKD are not only at a higher risk of thrombosis, they are also at increased risk of bleeding. Furthermore, the pharmacokinetics and pharmacodynamics of many anticoagulant therapies are significantly affected by renal dysfunction. In addition, patients with advanced CKD are often systematically excluded from major clinical trials. As such, the decision on whether to anticoagulate or not, and if so with what agent, poses significant challenges. A solid understanding of the condition in question and the available treatments is required to make an informed judgement call. An in-depth appreciation of the advantages and disadvantages of the currently available anticoagulants is a key element in the decision-making process.
Original languageEnglish
Pages (from-to)151-155
JournalClinical Medicine, Journal of the Royal College of Physicians of London
Publication statusPublished - 18 Mar 2020


  • chronic kidney disease
  • venous thromboembolism
  • anticoagulation
  • haemorrhage
  • heparin


Dive into the research topics of 'Anticoagulant strategies for the patient with chronic kidney disease'. Together they form a unique fingerprint.

Cite this